Figure 1 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Le résumé fourni par la source

Study design. Abbreviations: AE, adverse event; AKT1, AKT serine/threonine protein kinase 1; ASCO/CAP, American Society of Clinical Oncology/College of American Pathologists; BID, twice a day; CDK4/6, cyclin-dependent kinase 4/6; DLT, dose-limiting toxicity; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; IM, intramuscularly; INV, investigator; ISH, in situ hybridization; IV, intravenously; mBC, metastatic breast cancer; mTOR, mammalian target of rapamycin; ORR, objective response rate; OS, overall survival; PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PFS, progression-free survival; PO, orally; PTEN, phosphatase and tensin homolog; Q3W, once every 3 weeks; Q4W, once every 4 weeks; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1; RP2D, recommended phase 2 dose; SAE, serious adverse event; T-DXd, trastuzumab deruxtecan. aPer ASCO/CAP guidelines. bTargeted therapies such as CDK4/6, mTOR, or PI3K inhibitors. cPatients were assigned per predefined rules by a central system using interactive response technology, depending on HR status and line of therapy. dThe T-DXd + durvalumab + paclitaxel module was not investigated in the dose-expansion phase of the study. ePIK3CA/AKT1/PTEN alteration status was a preplanned molecularly defined subgroup of interest in the T-DXd + capivasertib module.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.